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Reactive oxygen species (ROS), including superoxide anion, hydrogen peroxide, and hydroxyl radical, can be formed as normal
products of aerobic metabolism and can be produced at elevated rates under pathophysiological conditions. Overproduction
and/or insuﬃcient removal of ROS result in signiﬁcant damage to cell structure and functions. In vitro studies showed that
antioxidants, when applied directly and at relatively high concentrations to cellular systems, are eﬀective in conferring protection
against the damaging actions of ROS, but results from animal and human studies showed that several antioxidants provide only
modest beneﬁt and even possible harm. Antioxidants have yet to be rendered into reliable and safe therapies because of their
poor solubility, inability to cross membrane barriers, extensive ﬁrst-pass metabolism, and rapid clearance from cells. There is
considerableinteresttowardsthedevelopmentofdrug-deliverysystemsthatwouldresultintheselectivedeliveryofantioxidantsto
tissuesinsuﬃcientconcentrationstoameliorateoxidant-inducedtissueinjuries.Liposomesarebiocompatible,biodegradable,and
nontoxicartiﬁcialphospholipidvesiclesthatoﬀerthepossibilityofcarryinghydrophilic,hydrophobic,andamphiphilicmolecules.
This paper focus on the use of liposomes for the delivery of antioxidants in the prevention or treatment of pathological conditions
related to oxidative stress.
1.Introduction
Oxidative stress (OS) is deﬁned as an imbalance between
the production of reactive oxygen species and antioxidant
defenses that can lead to cellular and tissue damage [1–8]. A
potential pharmacological strategy in preventing or treating
oxidant-induced cellular and tissue damage involves the
use of appropriate antioxidants. Antioxidants are substances
which are able to prevent, delay, or remove oxidative damage
to a molecule [4, 9–11]. Yet, their eﬃcacy is hindered with
challenges such as poor solubility, inability to cross cell-
membrane barriers, extensive ﬁrst-pass metabolism, and
rapid clearance of antioxidants from cells [12, 13]. To
improve the pharmacological and pharmacokinetic prop-
erties of antioxidants, diverse systems such as antioxidant
chemical modiﬁcations and coupling to aﬃnity carriers,
micelles, and liposomes are being developed [4, 13–18].
This paper focus on the use of liposomes for the deliv-
ery of antioxidants in the prevention or treatment of
several pathological conditions linked to oxidative stress.
Liposomes are artiﬁcial vesicles consisting of an aqueous
core enclosed in one or more phospholipid layers; water-
soluble compounds can be encapsulated in the aqueous core,
while lipid-soluble compounds can be incorporated into
the lipid bilayer of the liposome (Figure 1)[ 19–21]. Encap-
sulation of enzymatic antioxidants (superoxide dismutase
and catalase) or nonenzymatic antioxidants (glutathione, N-
acetylcysteine, CoQ10, curcumin, resveratrol, α-tocopherol,
and γ-tocopherol) in liposomes improves their therapeutic
potential against oxidant-induced tissue injuries, because
liposomesapparentlyfacilitateintracellulardeliveryandpro-
long the retention time of entrapped agents inside the cell.
2. OxidativeStress andthe Antioxidant
DefenseSystem
The involvement of oxidants in several pathological dis-
orders, including cancer, diabetes, cardiovascular diseases,2 Journal of Toxicology
chronic inﬂammatory disease, postischaemic organ injury,
neurodegenerative disorders, and xenobiotic/drug toxicity
has been widely accepted, but whether such oxidants are
the major cause of tissue injury in human disease or
simply produced during the development of injury is still
under debate [1–8]. Regardless, the interaction of reactive
oxygen species (ROS) with macromolecules, organelles, and
tissues results in damage. For example, membrane lipid
oxidation may result in an irreversible injury to the plasma
membrane [22]. Protein oxidation may lead to a loss of
critical sulphydryl groups in addition to modiﬁcations of
amino acids leading to the formation of carbonyl and other
oxidized moieties [23]. Attack of ROS on nucleic acids can
generate various modiﬁed bases in DNA which play a critical
role in carcinogenesis and aging [1].
In general, oxidative stress describes the result of an
increased ROS production and/or a decrease in their elim-
ination [24]. Such ROS include, but certainly not limited
to, superoxide anion, hydrogen peroxide, hydroxyl radical,
and lipid peroxides [25, 26]. Some of these species, such
as superoxide or hydroxyl radicals, are extremely unstable,
whereas others, like hydrogen peroxide, are freely diﬀusible
and relatively long lived. The sources of ROS may be exoge-
nousorendogenous[2,11].Duringtheirmetabolism,agents
such as paraquat or doxorubicin generate ROS resulting
in pneumotoxicity or cardiotoxicity, respectively [4, 27].
Intrinsically generated oxidants may be derived from the
electron transport chain in the mitochondria, with the most
important source of damaging oxidants being the phagocytic
cells (residential macrophages and recruited neutrophils)
that can generate ROS and reactive nitrogen species from
the NADPH oxidase assembly located on their cell surfaces
[2, 28, 29]. Other pathways that may participate in the
formation of ROS include xanthine oxidase in ischemia-
reperfusion and cytochrome P-450-dependent activation of
xenobiotics [11, 26].
Sequential reduction of molecular oxygen leads to the
formation of superoxide anion, hydrogen peroxide, and
hydroxyl radical. The univalent reduction of molecular
oxygen forms superoxide anion in a reaction mediated by
enzymes such as xanthine oxidase and NAD(P)H oxidase
or nonenzymatically by redox-reactive compounds such
as the semiubiquinone compound of the mitochondrial
electron transport chain [11, 26, 30]. Superoxide dismutases
convert the superoxide anion into hydrogen peroxide which
in the presence of reduced transition metals (e.g., ferrous
or cuprous ions) is metabolized to the highly reactive
hydroxyl radical [30]. Other reactive species include nitric
oxide, lipid radicals, peroxynitrite, and hypochlorous acid
[11, 29]. Nitric oxide is synthesized from the guanidine
group of L-arginine by a family of enzymes termed nitric
oxide synthases. Simultaneous generation of nitric oxide and
superoxide anion favors the production of a strong oxidant,
the peroxynitrite anion, which may account for some of the
deleterious eﬀects associated with nitric oxide production
[31]. All these reactive oxygen species are potentially very
reactive molecules and, at high enough concentration, result
in damage to critical cellular constituents (such as proteins,
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Figure 1: Schematic representation of a liposome containing
antioxidants. Liposomes are artiﬁcially prepared vesicles made
of lipid bilayer. Water-soluble compounds (e.g., N-acetylcysteine
(NAC)) can be encapsulated in the aqueous phase, while lipid-
soluble compounds (e.g., α-tocopherol) can be incorporated into
the lipid bilayer of the liposome.
nucleic acids, carbohydrates, and lipids) resulting in cell
necrosis [11, 26, 28, 29].
At physiological low levels, ROS function as “redox
messengers” in intracellular signaling and regulation. Redox
signaling is a well-recognized stress response that leads
to a variety of downstream eﬀects including increased
expression of protective and repair enzymes [32, 33]. There
is also mounting evidence that redox signaling is part of
normal metabolism in nonstressed cells. In this situation,
endogenously generated oxidants act as second messengers
for receptor agonists such as growth factors and hormones,
signaling the proliferative or metabolic changes associated
with these ligands [32, 33]. Oxidants can activate and
inactivate transcription factors, membrane channels, and
metabolic enzymes, and modulate calcium-dependent and
phosphorylation signaling pathways. These processes incor-
porate the major regulatory networks of cells, giving redox
signals the capacity to stimulate and adjust most aspects of
cell physiology [34].
Exposure to reactive oxygen species from a variety of
sources has led organisms to develop a series of defense
mechanisms [9, 35]. The harmful eﬀects of ROS are coun-
terbalanced by the antioxidant action of both antioxidant
enzymes and nonenzymatic antioxidants [30]. Antioxidants
have been deﬁned as substances that are able to prevent,
delay, or remove oxidative damage to a molecule [36]a n d
may be categorized in the following groups: (i) those aimed
at preventing the generation and distribution of reactive
oxygen and nitrogen species (e.g., the eﬀective control
of iron distribution and the destruction of peroxides by
catalase or by glutathione peroxidase), (ii) those aimed at
reactive metabolite scavenging including the maintenance of
eﬀective levels of antioxidants, such as vitamin E, vitamin C,
β-carotene,andglutathioneaswellastheenzymesuperoxideJournal of Toxicology 3
dismutase, and (iii) those aimed at free radical repair,
particularly the maintenance of eﬀective levels of glutathione
[4, 10, 11, 36].
The antioxidant enzymes found in living cells include
the superoxide dismutase, catalase, glutathione peroxidase,
peroxiredoxins, and thioredoxin reductase [4, 10, 11, 13,
25, 36–38]. These antioxidant enzymes are not consumed
during their catalytic actions, and they have high aﬃnity
and rate of reaction with ROS consequently allowing more
eﬀective protection against acute massive oxidative insults.
Superoxide dismutases (SODs) are metalloenzymes that
catalyze the conversion of superoxide anion to hydrogen
peroxide and include the cytosolic copper and zinc con-
taining form (Cu-Zn-SOD), the mitochondrial manganese-
containing SOD (MnSOD), and an extracellular form (EC-
SOD) [39]. Catalase, which catalyzes the detoxication of
hydrogen peroxide to water and oxygen, occurs abundantly
in the body, with the highest activity in the liver, followed by
erythrocytes, then the lungs [13, 25]. Glutathione peroxidase
plays a major role in the detoxication of hydrogen peroxide,
otherhydroperoxides,andlipidperoxidesviatheglutathione
redox cycle [11, 25]. The thioredoxin system, consisting
of thioredoxin reductase in conjunction with thioredoxin
and NADPH, is a ubiquitous oxidoreductase system with
antioxidant and redox regulatory roles; mammalian thiore-
doxin reductase has a highly reactive active site selenocys-
teine residue resulting in a profound reductive capacity,
reducing several substrates in addition to thioredoxin [37].
Peroxiredoxins are ubiquitous thiol-dependent peroxidases
that accomplish the same function as other antioxidant
enzymes such as catalase and glutathione peroxidase, but
their catalytic activity is lower than that of these enzymes.
Peroxiredoxin 6 is a bifunctional protein with both GSH per-
oxidase and phospholipase A2 activities that play important
physiologicalrolesinantioxidantdefenseandlungsurfactant
metabolism [38, 40].
Nonenzymatic antioxidative systems are not as speciﬁc
as enzymatic ones, but they serve as the ﬁrst line of defense
and are, therefore, of high importance in cellular response
to oxidative stress. The major nonenzymatic antioxidants
include vitamin C (ascorbic acid), vitamin E (tocopherols
and tocotrienols), glutathione, carotenoids, ﬂavonoids, and
other micronutrients. Vitamin C, a water-soluble vitamin,
is eﬀective in scavenging ROS, including hydroxyl radical,
aqueous peroxyl radicals, and superoxide anion [10]. Vita-
min E, the principal antioxidant in the body, is composed
of four tocopherols and four tocotrienols, and, due to
its lipophilicity, it is present in all cellular membranes
[41]. The antioxidant functions of vitamin E include the
termination of chain reactions in polyunsaturated fatty acids
in cell membranes from peroxidation by scavenging peroxyl
radicals in membranes and neutralizing the highly reactive
singlet oxygen molecules [42]. Glutathione (GSH) is the
most abundant nonprotein thiol in living organisms and
can exert its protective eﬀects by acting as a nucleophile to
form conjugates with many xenobiotic compounds and/or
their metabolites and serve as a reductant in the metabolism
of hydrogen peroxide and other organic hydroperoxides,
a reaction catalyzed by glutathione peroxidases found in
cytosols and mitochondria of various cells [43, 44]. In
humans, a number of neurodegenerative and neuropsy-
chiatric conditions are associated with disturbances in
glutathione [45]. Repletion and maintenance of neuronal
GSH is, therefore, important to cell health and viability and
could provide therapeutic beneﬁt in situations when GSH
is deﬁcient. Carotenoids are a class of natural fat-soluble
pigments found principally in plants, the most abundant
in the diet being beta-carotene, lycopene, lutein, beta-
cryptoxanthin, zeaxanthin, and astaxanthin. The antioxidant
actions of carotenoids are based on their singlet oxygen
quenchingpropertiesandtheirabilitytotrapperoxylradicals
[46, 47]. Flavonoids (i.e., quercetin) and phenolic acids (i.e.,
resveratrol) are polyphenolic substances that have chemical
structures supporting the scavenging of free radicals and the
chelation of redox-active metals [48].
3. AntioxidantTherapy
Antioxidant therapy has been deﬁned as any treatment that
prevents or decreases the adverse eﬀects of oxidants. One of
the strategies for pharmacological modiﬁcation of oxidant-
mediated tissue injury focuses on increasing the antioxidant
capacityofcellsorpreventingthegenerationofROS[12,13].
Theeﬀectivenessofexogenousantioxidantstoprotecttissues
from oxidant stress in vivo depends on the antioxidant used,
its physicochemical and biopharmaceutical properties, its
availabilityatthesiteofaction,and,thenatureoftheoxidant
stress [12, 13].
Only a few available drugs have been documented to
possess antioxidant properties that might contribute to their
eﬃcacy. For example, N-acetylcysteine is used as a mucolytic
agentandinthetreatmentofacetaminophenpoisoning[86],
deferoxamine is used as a chelating agent in iron overload
[87], and probucol, calcium antagonists, β-adrenoreceptor
antagonists, antiarrhythmic drugs, and statins are used in
the treatment of cardiovascular diseases [88, 89]. Most of
the studies examining the prophylactic or therapeutic eﬀects
of antioxidants against several diseases and disorders have
resulted from epidemiological studies in ethnic groups who
have diﬀerent lifestyles and have been exposed to diﬀerent
environmental factors [13]. For example, the use of red
wine in the diet of French people is associated with lower
incidences of cardiovascular disease [13]. Also, the high
level of antioxidants in the Mediterranean diet has also
been associated with lower incidences of cardiovascular
disease and morbidity and mortality [13]. Other studies
have focused on the use of antioxidants by patients as
dietary supplements in the hope of maintaining health,
preventing disease, or reducing the toxicity of chemotherapy
and radiotherapy, but the results so far are not conclusive
[12, 13, 90].
The beneﬁt of dietary antioxidants has been explored
in both in vitro and in vivo systems. Most antioxidants,
whenapplieddirectlyandatrelativelyhighconcentrationsto
cellularsystemsin vitro,a r ee ﬀective in conferring protection
against oxidant insults. On the other hand, results from
studies in animals and humans have revealed that several
antioxidants provide only modest beneﬁt and have yet to4 Journal of Toxicology
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Figure 2: Preparation of liposomal-N-acetylcysteine (L-NAC). L-
NAC is prepared from a mixture of DPPC and NAC in a 1:1 molar
ratiobyadehydration-rehydrationmethod.Thelipidsaredissolved
in chloroform in a round-bottomed ﬂask and dried at 45◦Cw i t ha
rotary evaporator. The lipid ﬁlm is dried with nitrogen to eliminate
traces of chloroform and hydrated with a solution of NAC and
subsequently sonicated. Sonication is a simple method for reducing
the size of liposomes. Upon rehydration, free NAC is separated
by high-speed centrifugation (24400g at 4◦C, for 30min), a step
performed twice. At the end of this procedure, the liposomal vesicle
size is usually below 200nm mean diameter with an encapsulation
eﬃciency of 35% NAC.
be rendered into reliable and safe antioxidant therapies. For
example, exposure of animals to the antioxidant enzymes
superoxide dismutase and catalase has been encountered
with antigenicity and immunogenicity problems [91, 92],
and both of these enzymes are poorly absorbed from and
rapidly degraded in the gastrointestinal tract [13]. Other
studies have shown that ﬂavonoids possess potent antiox-
idant activity in vitro, but their antioxidant action in vivo
has been challenged by studies examining the bioavailability
of ﬂavonoids, which indicate that they reach only very low
concentrations in human plasma after the consumption
of ﬂavonoid-rich foods [93]. In addition, most ﬂavonoids
are extensively metabolized in vivo,w h i c hc a na ﬀect their
antioxidant capacity [93]. It is obvious that the failure of
antioxidants to seriously modify the injurious actions of
oxidants is primarily attributed to their physicochemical
characteristics and/or pharmacokinetic properties without
excluding other possibilities such as some antioxidants also
have prooxidant activities, particularly in the presence of
transitional metals [94–97]. Experimental evidence, there-
fore, supports the need for the development of formulations
that would enhance the delivery and retention of antioxi-
dants in the tissues. Strategies to improve the eﬀectiveness
of antioxidants are focused on chemical modiﬁcations of
antioxidants (e.g., attachment of masking pegylated (PEG)-
groups), coupling of antioxidants to aﬃnity carriers (e.g.,
antibodies against cellular adhesion molecules) and drug-
delivery systems such as micelles and liposomes [4, 13–
15, 17]. In this paper, we will address the role of liposomes
as a delivery system for antioxidants.
4. Liposomes
Liposomes are nanosized artiﬁcial vesicles of spherical shape
that can be produced from natural or synthetic phospho-
lipids. The polar head groups are located at the surface of the
membranes, in contact with the medium, whereas the fatty
acid chains form the hydrophobic core of the membranes,
shieldedfromthewater.Polarmoleculescanbeencapsulated
in the aqueous core, while hydrophobic molecules dissolve
in the bilayers of liposomes [19]. Lipid ﬁlm hydration is
the simplest method for the encapsulation of water-soluble
drugs; a lipid ﬁlm is hydrated with an aqueous solution con-
taining the drug (Figure 2). Entrapment eﬃciency may vary
depending on: (i) the compound itself (charge, size, solubil-
ity, etc.), (ii) the lipid variations (a single type or a mixture
of lipids, composition, charge, etc.), and (iii) the prepara-
tion methods. The manipulation and design of liposomes
endowed with the ability for targeting speciﬁc cell sites (or
alternately, the temporary avoidance of these sites), results
inlongcirculation,increasedbiodistribution,andfavourable
pharmacodynamics [98–100]. Currently, a number of lipo-
some formulations are in clinical use to combat cancer and
infectious diseases, while others await clinical trial outcomes.
For example, while DaunoXome, Doxil, and Ambisome
are currently clinically approved, CPX-1 and LE-SN38 are
examples of liposomal-based drugs that encapsulate a topoi-
somerase I inhibitor and are currently in Phase-II clinical
trials for the treatment of colon or colorectal cancer [100].
Some of the setbacks and disadvantages of liposomes include
time-consuming preparation techniques, low entrapment
volumes, and toxicity concerns due to the presence of
residual toxic organic compounds during preparation [98].
The lipids used for the preparation of liposomes
are predominantly phospholipids or surfactants which
form bilayers similar to those found in biological mem-
branes. The surfactants dimyristoyl-phosphatidyl-glycerol
(DMPG), dimyristoyl-phosphatidylcholine (DMPC), dipal-
mitoyl-phosphatidylcholine (DPPC), and desaturated-phos-
phatidylcholine (DSPC) are naturally occurring but can be
produced synthetically as well. Extensive testing of these
phospholipids has revealed them to be remarkably safe
for pharmaceutical use. For example, phosphatidylcholine
(i.e., DPPC) (a phospholipid that carries no net charges, is
the major constituent of cell membranes, and it provides
a structural framework for the membrane and maintains
the permeability barrier) is well tolerated in animal and
human studies. Inhaled nondrug containing liposomes (15
and 150mg of lipid DPPC/mL) for 1 hour on pulmonary
function and on oximetry in healthy nonsmoking volunteers
showed that liposome inhalation is well tolerated, and no
oxygen desaturation, decrements in pulmonary function, or
side eﬀects were noted [101]. Other investigators have uti-
lized ﬂuorescein-labelled liposomes to examine the clearance
ofaerosolizedliposomesfromthelungsofhumanvolunteers
and reported no untoward side eﬀects [102]. Intravenous
administration of DPPC (5 to 50mg of lipid) did not induce
immediate or delayed toxicity in mice and did not produce
any changes in body weight and weight of major organs 2
weeks after administration. It has been reported that the
toxicity of intravenously administered liposomes composed
of DPPC is so low that accurate assessment of an LD50 value
is diﬃcult and has been estimated to be of the order of
10g/kg in mice [103]. However, it is important to note that
addition of other constituents to liposomes in order to alterJournal of Toxicology 5
stabilityorkineticscanresultinanincreaseintoxicpotential,
particularlyonparenteraladministrationofliposomes[104].
A potential problem with conventional liposomes, par-
ticularly when delivered intravenously, is their rapid removal
from circulation by cells of the reticuloendothelial system
(RES) particularly in the liver and spleen [14, 105]. To
circumvent the phagocytic cells of the immune system and
hence enhance their half-life in the circulation, “stealth
liposomes” have been designed [14, 105]. Stealth liposomes
are created by coating the liposomes with a layer of
polyethylene glycol-phosphatidylethanolamine (PEG lipo-
somes). PEGylation is the process of covalent attachment of
polyethylene glycol polymer to another molecule masking
the agent from the host’s immune and metabolic systems
and creating a shield around the pegylated agent due to its
large hydrodynamic volume, thus protecting it from renal
clearance and consequently prolonging its circulatory time
[14, 105, 106].
5. LiposomesasanAntioxidantDeliverySystem
Liposomes have been considered to be excellent models of
cell membranes and have been used for the evaluation of the
antioxidant properties of several lipophilic and hydrophilic
antioxidants against oxidant insults. As a drug delivery
system, liposomes have been used for the transport of water-
soluble and lipid-soluble antioxidants as well as antioxidant
enzymes to diﬀerent organs and tissues for the treatment
of oxidative stress-induced damage. Up-to-date, delivery of
molecules with antioxidant properties to diﬀerent organs
and tissues include the lipophilic antioxidants α-tocopherol
[107, 108]a n dC o Q 1 0[ 13, 109, 110], the hydrophilic
antioxidants glutathione, N-acetylcysteine [64, 111, 112],
and quercetin [13, 83, 113], and the antioxidant enzymes
superoxide dismutase and catalase [4, 14]( Table 1). Lipo-
somes can facilitate intracellular delivery of several thera-
peutic agents via fusion with the plasma membrane lipids,
receptor-mediated endocytosis, and phagocytosis[114–116].
5.1. Liposomal Superoxide Dismutase (SOD) and/or Catalase
(CAT). The eﬀectiveness of the antioxidant enzymes, SOD
and CAT, in the treatment of oxidant-induced injuries
is limited because of their unfavorable physicochemical
properties [13, 91, 92, 117, 118]. SOD is unable to cross cell
membranes due to its high molecular mass (which prevents
intracellular transport) or its charge (which prevents its
adherence to targets) and possess immunogenic properties
[15, 16, 91]. To enhance their eﬀectiveness, polyethylene
glycol was attached to antioxidant enzymes (pegylated SOD
and/or pegylated CAT), an approach shown to increase
their in vivo half-lives, cellular uptake by endothelial cells,
and eﬀectiveness in preventing pulmonary oxygen toxicity
in rats [119, 120]. However, when compared to liposomal
entrapped SOD and CAT, PEG antioxidant enzymes are less
protective against lung injury from continuous hyperoxia;
endothelial cells treated with liposomal entrapped SOD and
CAT increase the activity of these enzymes by 44-fold within
2hours[119,121].Anotherstrategyinvolvestheconjugation
ofSODandCATwithanantibodytoplatelet-endothelialcell
adhesion molecule-1 (PECAM-1) which bind to endothelial
cells and alleviate oxidative stress in cell culture models as
well as a mouse model of vascular oxidative stress [122–124].
Such validated strategies may be used eﬀectively to develop
future liposomal therapeutics by conjugating antibodies and
other molecules to liposomes in order to provide speciﬁc
targetingtoendothelialcellsoranyothercelltype[125,126].
The pharmacokinetic proﬁle of the antioxidant enzymes
alsoprovideshindranceintheireﬀectiveuseinthetreatment
of oxidant injuries. Intravenously administered SOD shows
a biological half-life of a few minutes, and enteral admin-
istration is ineﬀective due to biodegradation of the enzyme
in the gastrointestinal system [15, 16, 118]. On the other
hand, systemic administration of liposomally encapsulated
superoxide dismutase and catalase prolongs their circulating
half-life and enhances their protection in animal models of
oxidant-induced organ injuries [49, 57, 58]. For example,
the short half-lives of native SOD and catalase in circulating
blood and their inability to cross the blood-brain barrier
limit their therapeutic usefulness in treating ischemic brain
injury. Intravenous administration of Cu, ZnSOD liposomes
facilitates the delivery of SOD into the brain, not only in
the infarct but also in the noninfarcted subcortical area,
resulting in signiﬁcantly elevated levels of SOD activity
and protection against cerebral ischemia/reperfusion injury
[53–55]. Also, the addition of polyethylene glycol to the
surface of the liposomes gives the liposomes a hydrophilic
“sterically stabilized” surface, a property that contributes to a
lower aﬃnity of macrophages of the mononuclear phagocyte
system (MPS) for the circulating liposome particles and con-
sequently to an even extended prolonged blood circulation
(more than 5-fold prolongation of liposome circulation time
in blood) [127]. Systemic administration of PEG-liposomes
for targeting SOD to arthritic sites with that of non-PEG-
liposomes containing stearylamine in rats with adjuvant
arthritis demonstrate that PEG-liposomes are superior with
respect to circulation time and extent of localization at
arthritic sites [50].
Intratracheally administered surfactant liposomes, en-
capsulating CuZn-superoxide dismutase and catalase, in-
creases the alveolar type II cell antioxidant activity and
protects cells against oxidant stress in the lungs of adult,
premature or newborn animals [59–61, 65]) or against
bleomycin-induced lung injury [62, 63]. The coinstillation
with 2-chloroethyl ethyl sulﬁde (CEES) of liposomes con-
taining pegylated- (PEG-) catalase (CAT), PEG-superoxide
dismutase (SOD), or the combination, greatly attenuated
the development of lung injury [64]. Results from a limited
number of clinical studies suggest that liposomal superoxide
dismutase might protect against radiation-induced ﬁbrosis
[51, 52]. The biological half-life of recombinant human
Cu/Zn SOD (rhSOD) within the systemic circulation by
liposomal encapsulation and aerosolization into the lungs of
pigs leads to long-term and uniform uptake into systemic
circulation without acute deleterious eﬀects on respiratory
tract suggesting that aerosolization of liposomal rhSOD6 Journal of Toxicology
Table 1: Antioxidants delivered as liposomal formulations in animal models of oxidative stress.
Antioxidant Route of
administration Experimental model Target organ Reference(s)
iv Acetaminophen poisoning (rat) Liver [49]
iv (PEG-Liposome) Rheumatoid arthritis (rat) Paws [50]
SOD im Radiation-induced injury (human) Skin and underlying tissues [51, 52]
iv Cold-induced brain injury (rat) Brain [53]
iv Cerebral ischemia-carotid artery occlusion Brain [54, 55]
subgingivally Peridontitis (dogs) Gingiva [56]
iv Hyperoxia Lung [57, 58]
it Oxidative stress-induced injury
(Xanthine/xanthine oxidase ) (rabbit) Lung [59]
SOD and/or CAT it Hyperoxia (rat) Lung [60]
it Hyperoxia (premature rabbit) Lung [61]
it Bleomycin-induced injury (rat) Lung [62, 63]
It (PEG-Liposome) 2-chloroethyl ethyl sulﬁde (CEES) (rat) Lung [64]
CAT it Hyperoxia (rat) Lung [65]
oral Atherosclerosis (mice) Aortic arch [66]
iv Paracetamol poisoning (mice) Liver [67]
GSH it Human-premature infants Lung [68]
Parkinson’s disease In vitro neuronal/glial cell
cultures [69]
it 2-chloroethyl ethyl sulﬁde (CEES) (rat) Lung [64, 70]
GSH/α-tocopherol it Paraquat poisoning Lung [71]
it Shock (rat) Lung [72]
NAC iv Acetaminophen poisoning (mice) Liver [73]
it 2-chloroethyl ethyl sulﬁde (CEES) (rats) Lung [70]
iv LPS-induced injury (rat) Lung [74]
iv LPS-induced injury(rat) Liver [75]
α-tocopherol it Bleomycin (rat) Lung [76]
it Paraquat poisoning Lung [77]
it Phorbol-myristate acetate (rat) Lung [78]
ip Melphalan toxicity (mice) Lung [79]
α-tocopherol/L-
ascorbic
acid
i v P a r t i a lc e r e b r a li s c h e m i a( r a t ) B r a i n [ 80]
α,γ,δ-
tocopherols/NAC it 2-chloroethyl ethyl sulﬁde (CEES) (guinea pigs) Lung [81]
Quercetin intraventricular Myocardial injury (rats) peroxynitrite-induced
myocardial injury in isolated hearts and animals Heart [82]
iv Arsenite poisoning (rats) Liver [83]
CoQ10 topical Photoaging Skin [84]
Curcumin oral Bioavailability study Plasma [85]
Iv: intravenous, It: intratracheal, Ip: intraperitoneal, Im: intramuscular, and PEG: polyethylene glycol.
could be a feasible strategy for administration of radical
scavenging enzymes for treatment of systemic diseases [128].
The local application of liposome-encapsulated SOD
has been shown to confer beneﬁcial eﬀects as well. Sub-
gingival application of liposome-encapsulated SOD with
scaling and root planning suppressed periodontal inﬂam-
mation on experimentally induced periodontitis in beagle
dogs, a treatment eﬀect attributed to the slow washing of
the formulation from the periodontal pocket due to the
good bioadhesive properties of the vehicle [56]. Topical
application of cationic liposome-encapsulated SOD to rat
jejunum prior to induction of oxidative injury in situ was
found to signiﬁcantly enhance the antioxidant eﬀect of
SOD against the induced oxidative damage in the jejunalJournal of Toxicology 7
mucosa, compared with their free forms; this eﬀect was
caused by the increased mucosal adhesion of the liposomes
which potentially provide protection for the SOD against
proteolysis and premature scavenging by mucin components
[129]. In another study, topical application of liposomal-
encapsulated SOD reduced postburn wound size and edema
formation for the reason that liposomes enhanced the
antioxidant eﬀect of SOD against the neutrophil-mediated
oxidant injury by promoting the controlled sustained release
of SOD at the site of injury [130].
5.2. Liposomal Glutathione. Glutathione in its reduced
form (GSH) is the most powerful intracellular antioxidant.
Decreases in circulating and intracellular concentrations of
GSH levels can result in a lowered cellular redox potential
inﬂuencing the translocation of the transcription factor NF
kB which regulates the synthesis of cytokines and adhesion
molecules [131]. One possibility to protect cells from
damage caused by reactive oxygen species is to restore the
intracellular glutathione levels. Cellular GSH concentration
can be inﬂuenced by exogenous administration of GSH (as
intravenous infusion or as aerosol) or glutathione esters
[131]. The systemic bioavailability of orally administered
GSH and glutathione monoethyl ester (GSHE) in the rat is
low without aﬀecting the circulating concentrations of GSH
and cysteine, while intravenous administration of GSH or its
ester results in rapid elimination albeit slower for the GSHE
[132, 133]. Dietary glutathione is not possible to increase
circulating glutathione to a clinically beneﬁcial extent by the
oral administration of a single dose of glutathione (3 grams)
because of hydrolysis of glutathione by intestinal and hepatic
gamma-glutamyltransferase [134]. However, consumption
of liposomal glutathione (50mg/kg/day) by atheroscle-
rotic apolipoprotein E-deﬁcient (E0) mice (which develop
atherosclerotic lesions with many features common with
human lesions) for 2 months signiﬁcantly reduced serum
and macrophage oxidative stress, macrophage cholesterol
mass, and as a result of these eﬀects, signiﬁcantly attenuated
atherosclerosis development when compared to mice that
consumed similar concentration of control liposomes [66].
In another study, glutathione injected intravenously 2 hours
before acetaminophen administration as a liposomal formu-
lation was more eﬀective than soluble GSH in protecting
against drug-induced liver necrosis lipid peroxidation, and
hepatic glutathione depletion [67].
In animal studies where GSH is administered intratra-
cheally, only 1%-2% of the dose administered remained in
the lung 24 hours after treatment, while liposome encapsu-
lation improved the pulmonary retention of GSH, with 18%
and 10% of the dose administered remaining in the lung 24h
and 48h aftertreatment[135, 136]. Accordingly, Suntres and
Shek [71] showed that intratracheal instillation of liposome-
entrapped GSH yielded a better protection than free GSH
against paraquat-induced lung injury. The improved pro-
tection conferred by the liposomal GSH formulation was
attributedtotheextendedretentionofliposomesinthelung,
thus allowing a slow release of its GSH content [71]. In
another study, Smith et al. [136], showed that intratracheal
instillation of liposomal GSH was better than free GSH
in protecting against hyperoxia-induced lung injury [136].
Intratracheal liposomal glutathione instillation in ventilated
preterminfantsraisedthepulmonaryglutathioneandsignif-
icantlyreducedthelevelsoflipidperoxidationproducts[68].
It has been shown that liposomal GSH can be utilized for
repletion and maintenance of intracellular GSH in neuronal
cells and that liposomal GSH can provide signiﬁcant protec-
tion to neurons in a model system relevant to Parkinson’s
disease [69]. Neurons, like most other cells, do not possess
transportmechanismsforGSHandelevationofextracellular
GSH may pose potential toxicity problems that increase neu-
ronal vulnerability during ischemia, while the encapsulation
of GSH into lipid vesicles may avoid the potential toxicity
to neurons associated with extracellular GSH elevation and
may facilitate drug delivery to cells as has been shown for
other liposomal preparations [137, 138]. The concentration
needed for half maximal repletion in mixed mesencephalic
cultures containing approximately 70% neurons and 30%
glia was 100-fold less when GSH was encapsulated into lipo-
somalvesicles(4.75μMforliposomalGSHversus533μMfor
nonliposomal fully reduced GSH) [69].
6. Liposomal N-Acetylcysteine
N-acetylcysteine (NAC), a thiol-containing compound,
when administered in its conventional form did not protect
against the prolonged shock-induced acute lung injury but
when administered as a liposomal formulation directly to
the lungs of animals protected against the lung injury
[72] .T h ep r o t e c t i v ee ﬀect conferred by the liposomal NAC
occurred at low NAC doses [72], since liposomes are
known to prolong the retention of the antioxidant in the
lungs. L-NAC was also shown to have a prophylactic eﬀect
against both LPS-induced lung injuries [112]a n dL P S -o r
acetaminophen-induced hepatotoxicity in animals [73, 111].
N-Acetylcysteineisadrugusedintheclinicforthetreatment
ofacetaminophen-inducedhepatotoxicityandasamucolytic
agent. It possesses free radical-scavenging properties [4,
139] which are attributed to the nucleophilicity and redox
interactions of its thiol group [139, 140]. Additionally, NAC
is a source of cysteine, often the limiting precursor of de
novo GSH synthesis [139, 141, 142]. Furthermore, NAC has
been shown to inﬂuence redox-sensitive cell-signaling and
transcription pathways, such as NF-κB (which regulates pro-
inﬂammatory genes), and the p38, ERK1/2, SAPK/JNK, c-
Jun, and c-Fos pathways, among others, in a wide variety
of diﬀerent systems [139, 143]. N-Acetylcysteine has been
shown to promote cell growth and survival by activating the
MAPK pathway in response to ROS-induced injuries (which
normally lead to growth arrest and apoptosis) and is able
to limit inﬂammatory processes, such as the release of pro-
inﬂammatory cytokines [144].
The use of L-NAC was also investigated in half sulfur
mustard-induced acute lung injury in rats [64, 70]a n d
guinea pigs [108]. McClintock et al. [64]a n dH o e s e le t
al. [70] found that the eﬀects of airway instillation of 2-
chloroethyl ethyl sulﬁde (CEES), which has been shown
to induce acute lung injury (assessed by the leakage of
plasma albumin into the lung) in rats, were attenuated8 Journal of Toxicology
with immediate and 1-hour-delayed instillation of lipo-
somes containing reducing agents (i.e., NAC, GSH, or
resveratrol) or bifunctional liposomes (containing NAC and
GSH). Additionally, Hoesel et al. [70] found that airway
instillation of L-NAC was protective when administered
4 hours following CEES application in rats, as well as 3
weeks after CEES with bifunctional α-tocopherol and NAC
liposomes, though not with L-NAC alone after 3 weeks. Also,
the intratracheal administration of liposomal antioxidant
formulation containing alpha/gamma-tocopherol alone or
with NAC immediately after instillation of CEES attenuated
theshort-termaswellaslong-term(ﬁbrotic)eﬀectsofCEES-
induced lung injury [64].
Irrespective of the route of administration, liposomal
NAC was far superior to the conventional NAC. It has been
shown that intravenous administration of NAC alone at a
dose of 25mg/kg was not eﬀective in conferring any signiﬁ-
cant protection against LPS-induced hepatotoxicity while an
equivalent dose of NAC delivered as a liposomal formulation
conferred protection. This is not surprising, because most
studies have shown that intravenous administration of
conventional NAC preparations are demonstrated to be
eﬀective against animal models of sepsis or endotoxemia
at doses greater than 50mg/kg, iv [145–148]. Results from
pharmacokinetic studies have shown that following intra-
venous administration, NAC undergoes rapid and extensive
metabolism in the liver resulting in bioavailability of about
10% [149, 150]. This ﬁnding further supports the role of
liposomes in their use as a drug delivery system because of
their capability of delivering hepatoprotective agents to the
liver, an ideal approach to increase local concentration of
the agent, to reduce adverse eﬀects, and to achieve maximal
therapeutic eﬃciency. In a separate study examining the
safety and pharmacokinetics of L-NAC in control rats, it
has been demonstrated that the half-life of intravenously
administered L-NAC is signiﬁcantly increased by 4-fold from
6minto30min(unpublishedobservation).Similarly,results
presentedbyotherinvestigatorshaveshownthatintravenous
administration of drugs as liposomal formulations prolong
theircirculationtimeinbloodandincreasetheirdistribution
to major organs, including the lung [4, 13].
6.1. Liposomal Tocopherols. α-Tocopherol, the major com-
ponent of Vitamin E, is a lipid-soluble hydrocarbon com-
pound that partitions into lipid storage organelles and cell
membranes. It is an eﬃcient scavenger of lipid peroxyl
radicals and, hence, it is able to break peroxyl chain prop-
agation reactions in cellular membranes preventing lipid
peroxidation [151, 152]. In studies with model membrane
systems, α-tocopherol intercalates into phospholipid bilayers
with the long axis of the molecule oriented parallel to the
lipid hydrocarbon chains, and it is able to rotate about
its long axis and diﬀuse laterally within ﬂuid lipid bilayers
[152, 153]. Because of its membrane stabilizing eﬀect, α-
tocopherol has been used in the preparation of liposomes
for the delivery of several drugs [84, 154]. The maximum
amount of α-tocopherol that can be contained in egg
phosphatidylcholine or phosphatidylcholine liposomes is
approximately 33% α-tocopherol. α-Tocopherol alters the
membrane characteristics of liposomes by making them
morestableandlesspermeabletoaqueoussolutesandhighly
resistant to protein-induced disruption [155]. The suppres-
sion of protein-induced disruption is more pronounced
with α-tocopherol than with cholesterol (used in liposomal
preparation to increase the physical stability of liposomes
particularly in the presence of biological ﬂuids such as
plasma), even at lower molar ratios. Also, α-tocopherol in
liposomescanundergospontaneousintermembranetransfer
to an acceptor membrane without the fusion of the with
α-tocopherol liposomes [156]. Thus, liposomes containing
α-tocopherol (15 to 30mol%) may be useful for delivering
physiological quantities of this vitamin component or other
d r u g st oc e l l si nc u l t u r eo rt ot i s s u e sin vivo.
Many studies have clearly demonstrated the impor-
tant role of α-tocopherol in modulating oxidant-induced
cellular injury, permitting cells with high levels of the
antioxidant to become more resistant to oxidative insults.
It has been shown that the administration of vitamin E,
prior to an oxidative challenge, reduces the level of lipid
peroxidation in several tissues and improves survival [152,
157–159]. However, in contrast to our studies [4, 74–78,
160], where the intratracheal instillation of α-tocopherol
liposomes conferred a signiﬁcant protective eﬀect against
the acute lung injuries and inﬂammation induced by
several chemicals including paraquat, bleomycin, phorbol
myristate acetate, and lipopolysaccharide (LPS), the oral or
parenteral administration of conventional α-tocopherol to
animals oﬀered limited or no protection against paraquat
or lipopolysaccharide-induced lung damage [161–165]. In
our studies, the intratracheal instillation of α-tocopherol
liposomes achieved a substantially higher antioxidant level
in the lung, approximately 1mg/g lung weight [166], while
the amount of antioxidant recovered from the lungs of
animals after oral or parenteral administration of vitamin
E was most likely less than 40μg/g lung tissue [167, 168].
Vitamin E, used as oral supplements, is often in the form
of tocopheryl esters which are highly stable to oxidation
but are absorbed only after they have been unesteriﬁed by
the intestinal esterases. The active form of α-tocopherol is
highly viscous oil, practically insoluble in water and readily
oxidized by atmospheric oxygen. In our laboratory, attempts
were made to deliver α-tocopherol to the lungs of animals
by other means, but results from these studies showed that
organic solvents, such as ethanol and dimethylsulphoxide,
used to solubilize the viscous free α-tocopherol, were toxic
to the lung, and emulsifying agents and detergents, such as
polyethylene glycol and Tween 80, caused respiratory failure,
possibly by disrupting surface tension of the lung [166]. An
intravenous form of vitamin E, E-ferol, that contained dl-
(α)-tocopherol and polysorbate 80 was ﬁrst clinically used,
albeit without detailed safety tests, in the early 1980s in low-
birth-weight and premature infants for the treatment of the
retrolental ﬁbroplasias and resulted in severe adverse eﬀects,
including hepatomegaly and renal failure most likely due to
the excipient polysorbate 80 [169].
The eﬀectiveness of α-tocopherol-loaded liposomes has
been examined in tissue injuries other than the lung asJournal of Toxicology 9
well. Sinha et al. 2001 [80] showed that α-tocopherol-
loaded liposomes were protective against an experimental in
vivo rat model of global cerebral ischemia controlling more
eﬀectively the conjugated diene increment in the brain of
rats after ischemia and reperfusion of rats [80]. Liposomal
α-tocopherol formulations have been proven to be eﬀective
in tissue injuries induced by alkylating agents such as
melphalan, 2-chloroethyl ethyl sulﬁde (CEES), [79, 108].
7. Other Liposomal Antioxidants
7.1. Liposomal Coenzyme Q. Coenzyme Q (CoQ) is a
naturally occurring compound also known as ubiquinone.
It belongs to a homologous series of compounds that
share a common benzoquinone ring structure but diﬀer
in the length of the isoprenoid side chain; in humans
and a few other mammalian species, the side chain is
comprised of 10 isoprene units, hence it is called coenzyme
Q10 (CoQ10). CoQ10 has a fundamental role in cellular
bioenergetics as a cofactor in the mitochondrial electron
transportchain(respiratorychain)andis,therefore,essential
for the production of ATP. CoQ10 in its reduced form as
the hydroquinone (called ubiquinol) is a potent lipophilic
antioxidant and is capable of recycling and regenerating
other antioxidants such as tocopherol and ascorbate [170,
171]. Data from several laboratories have demonstrated
that CoQ10 pretreatment protects the myocardium from
ischemia-reperfusion injury via both antioxidant and bioen-
ergetic pathways [110]. However, the high molecular weight
and lipophilicity of CoQ10 makes it poorly water soluble
and consequently leads to low systemic availability [18].
Following oral administration of CoQ10 either as a powder
or as an oil suspension elicit practically no response in
human subjects and it takes days to increase the CoQ10
blood and possibly other tissue [109, 170]. The intravenous
administration of CoQ10 as a liposomal formulation raised
the serum and myocardial levels of CoQ10 and signiﬁcantly
improved the function and eﬃciency of myocardial tissue
and reduced oxidant injury observed following ischemia-
reperfusion [109] .S e v e r a la d v a n c e m e n t sh a v eb e e nm a d e
to enhance the bioavailability of CoQ10 using various
approaches like size reduction, solubility enhancement (by
soliddispersion,prodrug,complexation,andionization)and
use of novel drug carriers such as liposomes, microspheres,
nanoparticles, nanoemulsions, and self-emulsifying system
(see review by Beg et al. 2010 [18]).
Liposomal CoQ10 is a promising candidate for the
topical application of CoQ10. CoQ10 encapsulated in N-
trimethylchitosan-(TMC-)coatedliposomesisbeingexam-
ined as potential ophthalmic drug delivery system. TMC
exhibits an excellent absorption-enhancing eﬀect by opening
the tight junctions between adjacent cells of epithelial
cell monolayers [172] while Q10 ameliorates the oxidative
stress in the lenses, the most common damaging factor
for the development of cataract [173]. Also, cosmetically
applied CoQ10 has the ability to reduce photoaging, with
a corresponding decrease in wrinkle depth [84], but its
bioavailability in skin is poor. A liposomal formulation
composed of soybean phosphatidylcholine (SPC) and alpha-
tocopherol (Vit E) used to encapsulate CoQ10 for topical
application signiﬁcantly enhanced its accumulation (at least
twofold) in rat skin, compared with an unencapsulated
suspension. Prolonging the treatment time and increasing
the content of CoQ10 in the formulation both raised the
amount of CoQ10 in rat skin [84].
7.2. Liposomal Curcumin. Curcumin, a hydrophobic poly-
phenolic compound derived from dietary spice turmeric,
possesses diverse pharmacologic eﬀects including anti-
inﬂammatory, antioxidant, antiproliferative, and antiangio-
genic activities. Curcumin has been used extensively in
traditional medicine since ancient times as a household
remedy against various diseases, including hepatic disorders,
cough, sinusitis, rheumatism, and biliary disorders. In
the past few decades, a number of studies have been
carried out to conﬁrm curcumin’s potential role in treating
inﬂammatory disorders, cardiovascular disease, cancer,
AIDS, and neurological disorders [174–176]. The main
drawback associated with the therapeutic potential of
curcumin is its poor aqueous solubility and stability in
gastrointestinal ﬂuids, which leads to poor bioavailability
[175, 176]. Several novel drug-delivery approaches, includ-
ing microemulsions, nanoemulsions, liposomes, solid lip-
id nanoparticles, microspheres, solid dispersion, poly-
meric nanoparticles, and self-microemulsifying drug-
delivery systems have been used to enhance the bio-
availability and tissue-targeting ability of curcumin in vitro
and in vivo [175–177]. Oral administration of liposomal
curcumin increased its bioavailability and antioxidant
activity in plasma [85]. A recent study examining the
antitumor activity of liposomal curcumin against human
pancreatic carcinoma cells demonstrated that liposomal
curcumin inhibits pancreatic carcinoma growth and, in
addition, exhibits antiangiogenic eﬀects [178].
7.3. Liposomal Resveratrol. Resveratrol, the main active
polyphenol in red wine, has been implicated as a possi-
ble contributor to the cardiovascular protection conferred
by red wine consumption, since this compound can be
found in grapes among other fruits [179, 180]. The car-
diovascular eﬀect of resveratrol can, in turn, be related
with its proved capacity to act as a modulator on the
metabolism of lipoproteins inhibiting the oxidation of low-
density lipoproteins (LDLs), and inhibiting either platelet
aggregation or proatherogenic eicosanoids production by
humanplateletsandneutrophils.Thesepotentialtherapeutic
and prophylactic applications are, however, restricted by the
low bioavailability caused by its physical properties [179,
180]. Resveratrol has low water solubility and stability as
well as its is rapidly and extensively metabolized making its
clinical use challenging [181]. To our knowledge, there have
beenonlyafewstudiescomparingtheantioxidantproperties
of liposomal resveratrol with that of free resveratrol and
reported that the liposomal formulation is more eﬀective
in ameliorating the oxidant-induced cellular injury induced
from UV-B irradiation on human-derived renal epithelial
cells [182].10 Journal of Toxicology
7.4. Liposomal Quercetin. Quercetin is a polyphenolic
ﬂavonoid, commonly found in apples, onions, berries, and
red wine, with strong antioxidant and antiinﬂammatory
properties. Its use is limited by its low water solubility and
high rate of metabolism [183]. Pretreatment of animals
with the ﬂavonoid quercetin was ineﬀective in protecting
against carbon tetrachloride-induced hepatotoxicity. Carbon
tetrachloride is known to mediate its liver toxicity via free-
radical mechanisms including oxidative stress. Pretreatment
of animals with mannosylated liposomal quercetin signiﬁ-
cantly lowered the hepatotoxic eﬀect of carbon tetrachloride
[83]. In another study, it was demonstrated that quercetin-
ﬁlled liposomes improved the protective eﬀects of the
antioxidant against peroxynitrite-induced myocardial injury
in isolated cardiac tissues and anesthetized animals [82].
Pegylated liposomal quercetin signiﬁcantly improved the
solubility and bioavailability of quercetin and enhanced its
antitumour activity in immunocompetent C57BL/6N mice
bearing LL/2 Lewis lung cancer and in BALB/c mice bearing
CT26 colon adenocarcinoma and H22 hepatoma [113].
7.5. Liposomal Astaxanthin. Astaxanthin, is a red-orange
lipid-soluble carotenoid pigment with powerful antioxi-
dant and antinﬂammatory properties. As measured by a
ﬂuorometric assay based on visible-absorbing ﬂuorescent
probes that belong to the BODIPY class of dyes (BODIPY
581/591 C11 and BODIPY 665/676) to measure antioxidant
activities of antioxidants in a lipid environment, astaxanthin
possess an antioxidative capability 10-times stronger than
zeaxanthin, lutein, canthaxanthin, and β-carotene [184].
However, its use is often limited due to its poor water sol-
ubility and extremely low bioavailability when administered
orally. The transport and protective eﬀects of astaxanthin
in Hep3B and HepG2 cell lines challenged with gamma
radiation was far superior when the antioxidant was deliv-
ered with egg-yolk phosphatidylcholine liposomes [185].
Incorporation of astaxanthin into phosphatidylcholine mul-
tilamellar liposomes strongly reduced lipid damage when the
lipoperoxidation promoters—H2O2, tert-butyl hydroperox-
ide (t-ButOOH) or ascorbate—and Fe2+:EDTA were added
simultaneously to the liposomes [186] but also liposomal
encapsulation is also eﬀective in slowing the oxidation of
astaxanthin [185].
8. Liposomes ContainingMore than
One Antioxidant
It has been shown that the administration of liposomes
containing more than one antioxidant is more advantageous
in ameliorating oxidant-induced tissue injuries [57, 71, 80].
The antioxidant eﬀect of liposomal formulations containing
the enzymes SOD and catalase is more eﬀective than those
containing the individual antioxidant enzyme [57, 58]. The
therapeutic eﬃcacy of an antioxidant liposome formulation,
containing a lipophilic antioxidant, α-tocopherol, can be
improvedbyencapsulatinganotherantioxidant,suchasGSH
or L-ascorbic acid, in the same liposome preparation. These
liposomes, containing both α-tocopherol and GSH were
shown to be more eﬀective in protecting against oxidant-
induced lung injuries and lipid peroxidation than those
containing either α-tocopherol or GSH alone presumably
by α-tocopherol scavenging free radicals and stabilizing
biological membranes, while GSH, in addition to its ability
to act as a free radical scavenger, can also regenerate α-
tocopherol from its oxidized form [71]. Similarly, liposomes
containing both α-tocopherol and L-ascorbic acid were more
eﬀective in preventing the generation of conjugated diene in
cerebral tissues by the induction of global cerebral ischemia
and reperfusion than the those containing L-ascorbic acid
through a synergistic action [80]. In a more recent study,
it was shown that liposomes containing α-tocopherol, γ-
tocopherol, δ-tocopherol, and NAC were more eﬀective
than liposomes containing only NAC or GSH in blocking
the CEES-induced inﬂammatory response and lung injuries
[81, 108]. Liposomal delivery of curcumin and resveratrol
reducedcancerinprostate-speciﬁcPTENknockoutmiceand
this treatment eﬀe c tw a sf a rs u p e r i o rt ot h a ts e e nf o l l o w i n g
administration of each agent alone either in their free or
liposomal form [187].
9. Concluding Remarks
Antioxidant liposomes hold great promise in the treatment
of many diseases in which oxidative stress plays a signif-
icant role. Antioxidant enzymes and many of the other
antioxidants do not easily penetrate the plasma membrane
of cells and some have poor stability and short half-life in
plasma when administered through conventional delivery
modes. Liposomes are highly eﬃcient in terms of facilitating
antioxidant delivery and achieving prophylactic and ther-
apeutic eﬃcacies against oxidative stress-induced damage.
Liposomes can be prepared from natural phospholipids that
are biocompatible, biodegradable, and nonimmunogenic
and practically do not cause toxic eﬀects or antigenic
reactions. Although successful clinical applications in the
ﬁeld of drug delivery and treatment of cancer and systemic
or local fungal infections have demonstrated the potential
of the technology, clinical applications for the utilization
of liposomal antioxidant formulations have been limited.
Controversy on the eﬃcacy and safety of antioxidants still
exists due to lack of well-controlled clinical trials. There is a
need for large multicentre prospective randomized control
trials to assess the eﬀects of diﬀerent types and doses of
antioxidant in selected groups of patients in various chronic
and acute oxidative stress-related diseases. Perhaps, it is time
to vigorously seek alternative approaches and not simply
continue to study the use of antioxidants by patients as
dietary supplements in the hope of maintaining health and
preventing disease. The ability for precise adjustments of
liposome parameters such as size, charge, lipid composition,
and the conjugation of ligands coupled with the more
eﬃcient and safer loading techniques oﬀers the ﬂexibility
to make liposomes an eﬀective platform for the delivery of
antioxidants.
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